Investors’ expectations of lower interest rates were reflected in the major stock indexes and lower government bond yields.
Category: Stocks and Bonds
-
How Long Can This Uncanny Stock Market Prosper?
The U.S. market is top-heavy, with Nvidia occupying a bigger weight than any company in modern history. Risks abound, our columnist says.
-
Pop Mart Teases a Mini Labubu, Sending Stock Soaring
The grinning plush elves drove record revenue for the Chinese retailer in the first half of the year, and soon fans will have something new to lust after.
-
The Bull and Bear Cases for Another Market Rally
Stocks are still flying high. But doubts are creeping in about the S&P 500’s run, as some analysts have flashbacks to valuations during the dotcom boom.
-
Tariffs Are High. So Is the Stock Market.
Strong corporate earnings, mostly stable tariff rates and the expectation of interest rate cuts have eased worries of a market reckoning.
-
Tariffs Are High. So Is the Stock Market.
Strong corporate earnings, mostly stable tariff rates and the expectation of interest rate cuts have eased worries of a market reckoning.
-
Why Hands-Off Investing Pays Off
Put money into low-cost stock and bond funds, but don’t forget the rest of the recipe: Leave your investments alone.
-
Trump Crypto Firm Announces $1.5 Billion Digital Coin Deal
A publicly traded tech firm, ALT5 Sigma, plans to sell $1.5 billion of shares to fund the purchase of a cryptocurrency created by World Liberty Financial, which the Trumps control.
-
As Trump Curbs Wind Farms, Orsted Plans $9.4 Billion Share Offering
Shares of the Danish renewable energy developer tumbled after it would issue more stock to raise funds instead of divesting a stake in a wind farm off the U.S. coast.
-
Trump Seeks to Sell Fannie Mae and Freddie Mac Shares to Public Investors
More than a decade after the government bailed out the mortgage giants, the Trump administration is looking for a partial stock-market exit.
-
Markets Rise, Taking Steeper Tariffs in Stride
Major indexes in Asia and Europe posted gains and U.S. futures climbed in premarket trading.
-
How Ozempic Maker Novo Nordisk Lost Its Shine
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes.